27 May 2025 - Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, confirms that the Company’s Annual Report and Accounts for the period ended 31 December 2024 and the notice of Annual General Meeting (“AGM”) will be posted to shareholders today. Read more…
Poolbeg Pharma plc (AIM: POLB, ‘Poolbeg Pharma’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, is pleased to announce a retail offer via the BookBuild Platform (the “BookBuild Offer”) of new ordinary shares of 0.02 pence each (the “Ordinary Shares”) in the capital of the Company (the […]
Poolbeg Pharma plc (AIM: POLB, ‘Poolbeg Pharma’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces a proposed conditional fundraising (the “Fundraising”) to raise gross proceeds of, in aggregate, approximately £4.1 million through the issue of new ordinary shares of 0.02 pence each in the capital of the Company […]
20 May 2025- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces its audited results for the year ended 31 December 2024. Read more…
First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemo Study will evaluate safety of the combination and explore whether targeting PI3Kδ with immunotherapy may rebalance the immune system to prevent or reverse resistance to current standard immunotherapy/chemo in NSCLC Geneva, Switzerland and Amsterdam, […]
